The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Codelivery of an Optimal Drug/siRNA Combination Using Mesoporous Silica Nanoparticles To Overcome Drug Resistance in Breast Cancer in Vitro and in Vivo
Open accessAbstract
We used a multifunctional mesoporous silica nanoparticle (MSNP) carrier to overcome doxorubicin (Dox) resistance in a multidrug resistant (MDR) human breast cancer xenograft by codelivering Dox and siRNA that targets the P-glycoprotein (Pgp) drug exporter. The Pgp siRNA selection from among a series of drug resistance targets was achieved by performing high throughput screening in a MDR breast cancer cell line, MCF-7/MDR. Following the establishment of a MCF-7/MDR xenograft model in nude mice, we demonstrated that a 50 nm MSNP, functionalized by a polyethyleneimine-polyethylene glycol (PEI-PEG) copolymer, provides protected delivery of stably bound Dox and Pgp siRNA to the tumor site. The effective biodistribution and reduced reticuloendothelial uptake, as a result of our nanocarrier design, allowed us to achieve an 8% enhanced permeability and retention effect at the tumor site. Compared to free Dox or the carrier loaded with either drug or siRNA alone, the dual delivery system resulted in synergistic inhibition of tumor growth in vivo. Analysis of multiple xenograft biopsies demonstrated significant Pgp knockdown at heterogeneous tumor sites that correspond to the regions where Dox was released intracellularly and induced apoptosis. We emphasize that the heterogeneity originates in the tumor microenvironment, which influences the vascular access, rather than heterogeneous Pgp expression in the MDR cells. Taken together, these data provide proof-of-principle testing of the use of a dual drug/siRNA nanocarrier to overcome Dox resistance in a xenograft. The study also provides the first detailed analysis of the impact of heterogeneity in the tumor microenvironment on the efficacy of siRNA delivery in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Hrkach, J., Von Hoff, D., Ali, M. M., Andrianova, E., Auer, J., Campbell, T., De Witt, D., Figa, M., Figueiredo, M., Horhota, A., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003651 · Cited by 1,147
Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs
Sugahara, K. N., Teesalu, T., Karmali, P. P., Kotamraju, V. R., Agemy, L., Greenwald, D. R., & Ruoslahti, E. (2010) · Science · doi:10.1126/science.1183057 · Cited by 1,075
Xia, T., Kovochich, M., Liong, M., Meng, H., Kabehie, S., George, S., Zink, J. I., & Nel, A. E. (2009) · ACS Nano · doi:10.1021/nn900918w · Cited by 933
Self-citationMeng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J. I., & Nel, A. E. (2010) · ACS Nano · doi:10.1021/nn100690m · Cited by 902
Self-citationZhang, H., Ji, Z., Xia, T., Meng, H., Low-Kam, C., Liu, R., Pokhrel, S., Lin, S., Wang, X., Liao, Y.-P., et al. (2012) · ACS Nano · doi:10.1021/nn3010087 · Cited by 825
Self-citationChen, A. M., Zhang, M., Wei, D., Stueber, D., Taratula, O., Minko, T., & He, H. (2009) · Small · doi:10.1002/smll.200900621 · Cited by 671
Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment
Chow, E. K., Zhang, X.-Q., Chen, M., Lam, R., Robinson, E., Huang, H., Schaffer, D., Osawa, E., Goga, A., & Ho, D. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001713 · Cited by 556
Seven challenges for nanomedicine
Sanhai, W. R., Sakamoto, J. H., Canady, R., & Ferrari, M. (2008) · Nature Nanotechnology · doi:10.1038/nnano.2008.114 · Cited by 538
Meng, H., Xue, M., Xia, T., Ji, Z., Tarn, D. Y., Zink, J. I., & Nel, A. E. (2011) · ACS Nano · doi:10.1021/nn200809t · Cited by 509
Self-citation
Cited by
Multifunctional Mesoporous Silica Nanoparticles as a Universal Platform for Drug Delivery
Argyo, C., Weiss, V., Bräuchle, C., & Bein, T. (2014) · Chemistry of Materials · doi:10.1021/cm402592t · Cited by 903
Qian, X., Zheng, Y., & Chen, Y. (2016) · Advanced Materials · doi:10.1002/adma.201602012 · Cited by 882
Cancer nanomedicine: A review of recent success in drug delivery
Tran, S., DeGiovanni, P., Piel, B., & Rai, P. (2017) · Clinical and Translational Medicine · doi:10.1186/s40169-017-0175-0 · Cited by 879
Mesoporous silica nanoparticles for drug and gene delivery
Zhou, Y., Quan, G., Wu, Q., Zhang, X., Niu, B., Wu, B., Huang, Y., Pan, X., & Wu, C. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.01.007 · Cited by 706
Recent advances of cocktail chemotherapy by combination drug delivery systems
Hu, Q., Sun, W., Wang, C., & Gu, Z. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.022 · Cited by 625
Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years (and Beyond)
Lächelt, U., & Wagner, E. (2015) · Chemical Reviews · doi:10.1021/cr5006793 · Cited by 600
Croissant, J. G., Fatieiev, Y., Almalik, A., & Khashab, N. M. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201700831 · Cited by 594
Deng, Z. J., Morton, S. W., Ben-Akiva, E., Dreaden, E. C., Shopsowitz, K. E., & Hammond, P. T. (2013) · ACS Nano · doi:10.1021/nn4047925 · Cited by 516
Kemp, J. A., Shim, M. S., Heo, C. Y., & Kwon, Y. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.10.019 · Cited by 506
Gated Materials for On-Command Release of Guest Molecules
Aznar, E., Oroval, M., Pascual, L., Murguía, J. R., Martínez-Máñez, R., & Sancenón, F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00456 · Cited by 488
Meng, H., Wang, M., Liu, H., Liu, X., Situ, A., Wu, B., Ji, Z., Chang, C. H., & Nel, A. E. (2015) · ACS Nano · doi:10.1021/acsnano.5b00510 · Cited by 440
Self-citationLu, J., Liu, X., Liao, Y.-P., Salazar, F., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 440
Self-citationLiang, C., Xu, L., Song, G., & Liu, Z. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00458j · Cited by 435
Multifunctional mesoporous silica nanoparticles for biomedical applications
Xu, B., Li, S., Shi, R., & Liu, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01654-7 · Cited by 433
Synthetic amorphous silica nanoparticles: toxicity, biomedical and environmental implications
Croissant, J. G., Butler, K. S., Zink, J. I., & Brinker, C. J. (2020) · Nature Reviews Materials · doi:10.1038/s41578-020-0230-0 · Cited by 424
Self-citationGandhi, N. S., Tekade, R. K., & Chougule, M. B. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.001 · Cited by 394
Chang, Y., Yang, K., Wei, P., Huang, S., Pei, Y., Zhao, W., & Pei, Z. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201407272 · Cited by 366
Chen, Y., & Shi, J. (2016) · Advanced Materials · doi:10.1002/adma.201505147 · Cited by 356
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
Chemoresistance mechanisms of breast cancer and their countermeasures
Ji, X., Lu, Y., Tian, H., Meng, X., Wei, M., & Cho, W. C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108800 · Cited by 340
Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery
Kim, B., Park, J., & Sailor, M. J. (2019) · Advanced Materials · doi:10.1002/adma.201903637 · Cited by 298
Jiang, T., Mo, R., Bellotti, A., Zhou, J., & Gu, Z. (2014) · Advanced Functional Materials · doi:10.1002/adfm.201303222 · Cited by 298
Nanoparticle-mediated targeted drug delivery for breast cancer treatment
Liyanage, P. Y., Hettiarachchi, S. D., Zhou, Y., Ouhtit, A., Seven, E. S., Oztan, C. Y., Celik, E., & Leblanc, R. M. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.04.006 · Cited by 287
Nanomachines and Other Caps on Mesoporous Silica Nanoparticles for Drug Delivery
Chen, W., Glackin, C. A., Horwitz, M. A., & Zink, J. I. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00116 · Cited by 264
Self-citationLiu, X., Situ, A., Kang, Y., Villabroza, K. R., Liao, Y., Chang, C. H., Donahue, T., Nel, A. E., & Meng, H. (2016) · ACS Nano · doi:10.1021/acsnano.5b07781 · Cited by 262
Self-citationBuilding a Multifunctional Aptamer-Based DNA Nanoassembly for Targeted Cancer Therapy
Wu, C., Han, D., Chen, T., Peng, L., Zhu, G., You, M., Qiu, L., Sefah, K., Zhang, X., & Tan, W. (2013) · Journal of the American Chemical Society · doi:10.1021/ja4094617 · Cited by 260
Lipid based nanocarriers: a translational perspective
Mishra, D. K., Shandilya, R., & Mishra, P. K. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.05.021 · Cited by 258
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
“Meanwhile, the polymer attachment leaves the porous interior free for drug binding and delivery, thus establishing the rationale for simultaneous drug and nucleic acid delivery [26, 27].”
BackgroundMethodInfluentialHybrid nanoparticles for combination therapy of cancer
He, C., Lu, J., & Lin, W. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.029 · Cited by 174
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Huang, M., Hu, M., Song, Q., Song, H., Huang, J., Gu, X., Wang, X., Chen, J., Kang, T., Feng, X., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b03124 · Cited by 127
Self-citationHe, Z., Huang, J., Xu, Y., Zhang, X., Teng, Y., Huang, C., Wu, Y., Zhang, X., Zhang, H., & Sun, W. (2015) · Oncotarget · doi:10.18632/oncotarget.6243 · Cited by 112
Self-citationBabu, A., Wang, Q., Muralidharan, R., Shanker, M., Munshi, A., & Ramesh, R. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500259e · Cited by 94
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Liu, W., Zhu, Y., Wang, F., Li, X., Liu, X., Pang, J., & Pan, W. (2018) · Royal Society Open Science · doi:10.1098/rsos.181027 · Cited by 59
Metadata
- Authors
- Meng, H., Mai, W. X., Zhang, H., Xue, M., Xia, T., Lin, S., Wang, X., Zhao, Y., Ji, Z., Zink, J. I., & Nel, A. E.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-01-04
- Volume
- 7
- Issue
- 2
- Pages
- 994-1005
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2021385919
- Cited by
- 575
- References
- 44
- FWCI
- 24.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.